Update on Aurora Kinase Inhibitors in Gynecologic Malignancies

Author(s): Xia Tao , Hye S. Chon , Siqing Fu , John J. Kavanagh , Wei Hu .

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 3 , Issue 3 , 2008

Become EABM
Become Reviewer

Abstract:

Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis and play a role in tumorigenesis and tumor progression in humans. Aurora kinase A and Aurora kinase B are overexpressed in some gynecologic cancers, and their overexpression is associated with poor prognosis. Thus, targeting of Aurora kinases has become an attractive strategy for pharmaceutical companies, who have developed more than 30 Aurora kinase inhibitors for treatment of cancers. Some of these inhibitors have been shown to be effective in targeted therapies for human cancer, and others are currently being investigated. In this review, we summarize the most recent advances in preclinical studies and clinical trials of patented Aurora kinase inhibitors for gynecologic tumors.

Keywords: Gynecologic malignancies, Aurora kinases, Aurora kinase inhibitors

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 3
ISSUE: 3
Year: 2008
Page: [162 - 177]
Pages: 16
DOI: 10.2174/157489208786242322
Price: $58

Article Metrics

PDF: 2